Dublin, Ireland-based Endo International plc is a specialty pharmaceutical company focused on branded and generic pharmaceuticals products as well as over-the-counter medications through its operating companies. The company has several products including Lidoderm, Opana ER, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.
Endo has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 14.44%.
Currently, Endo has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endo beat second-quarter 2017 earnings. The company reported EPS of 93 cents while our consensus called for EPS of 74 cents.
Revenues: Revenues also surpassed expectations. Endo posted revenues of $875.7 million which beat Zacks Consensus Estimate of $847 million.
Key Stats: Revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.
2017 Guidance Lowered: Endo lowered its revenue guidance in the range of $3.38 billion to $3.53 billion for 2017 compared to $3.45 billion to $3.60 billion expected previously. The company expects earnings from continuing operations in the range of $3.35 to $3.65 per share as against $3.45 to $3.75 expected previously. The Zacks Consensus Estimate for earnings is $3.47 per share on revenues of $3.48 billion.
Pre-Market Trading: Shares were down more than 3% in the pre-market trading.
Check back later for our full write up on this ENDP earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Image: Bigstock
Endo (ENDP) Q2 Earnings Beat Estimates, 2017 Guidance Cut
Dublin, Ireland-based Endo International plc is a specialty pharmaceutical company focused on branded and generic pharmaceuticals products as well as over-the-counter medications through its operating companies. The company has several products including Lidoderm, Opana ER, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.
Endo has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 14.44%.
Endo International PLC Price and EPS Surprise
Endo International PLC Price and EPS Surprise | Endo International PLC Quote
Currently, Endo has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endo beat second-quarter 2017 earnings. The company reported EPS of 93 cents while our consensus called for EPS of 74 cents.
Revenues: Revenues also surpassed expectations. Endo posted revenues of $875.7 million which beat Zacks Consensus Estimate of $847 million.
Key Stats: Revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.
2017 Guidance Lowered: Endo lowered its revenue guidance in the range of $3.38 billion to $3.53 billion for 2017 compared to $3.45 billion to $3.60 billion expected previously. The company expects earnings from continuing operations in the range of $3.35 to $3.65 per share as against $3.45 to $3.75 expected previously. The Zacks Consensus Estimate for earnings is $3.47 per share on revenues of $3.48 billion.
Pre-Market Trading: Shares were down more than 3% in the pre-market trading.
Check back later for our full write up on this ENDP earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>